Industry News
– If successful, BridgeBio’s investigational gene therapy BBP-631 would be the first therapy for CAH to restore the body’s hormone and steroid balance by enabling people with CAH to make their own cortisol and aldosterone -Initial Phase 1/2 data readout anticipated in the second half of 2022 -BridgeBio’s gene therapy portfolio also includes a clinical stage…
Read MoreEBT-101 is a CRISPR-based therapeutic being developed as a potential functional cure for people living with HIV First-in-human trial is now open for enrollment Excerpt from the Press Release: SAN FRANCISCO, Jan. 27, 2022 (GLOBE NEWSWIRE) — Excision BioTherapeutics, Inc., a clinical-stage biotechnology company developing CRISPR-based therapies intended to cure viral infectious diseases, today announced…
Read MoreFunding from the Bill & Melinda Gates Foundation will support the development of Aridis’ inhaled formulation technology to deliver cost-effective monoclonal antibodies against influenza and COVID-19 Excerpt from the Press Release: OS GATOS, Calif., Jan. 27, 2022 /PRNewswire/ — Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat…
Read MoreEnrollment in the first dose escalation is complete with no safety issues reported to date Trial is designed to accelerate pelareorep’s development in Asian territories such as China, the world’s second-largest pharmaceutical market Excerpt from the Press Release: SAN DIEGO, Calif. and CALGARY, AB, Jan. 27, 2022 /PRNewswire/ — Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that its partner Adlai Nortye…
Read MoreExcerpt from the Press Release: Study met primary endpoint with 47.4% objective response rate Safety and tolerability profile consistent with previously reported data Planned BLA submission on track for later this year Conference call to be held today, Tuesday, January 25, 2022, at 8:30 AM ET WALTHAM, Mass., Jan. 25, 2022 (GLOBE NEWSWIRE) — Checkpoint…
Read MoreExcerpt from the Press Release: STI-1558, a novel oral Mpro inhibitor, effectively inhibits Omicron virus entry and replication in cells. STI-1558 is orally bioavailable with improved human liver microsomal stability to avoid using Ritonavir as a pharmacokinetic enhancer in humans. SAN DIEGO, Jan. 28, 2022 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today…
Read MoreStudy to evaluate safety, tolerability, pharmacokinetics, and potential to improve cognition Excerpt from the Press Release: CAMBRIDGE, Mass., Jan. 26, 2022 (GLOBE NEWSWIRE) — Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced that patient dosing has begun in its Phase 2a study…
Read MoreFirst line cohort of the Phase 1b/2 DEDUCTIVE study demonstrates promising efficacy and tolerability of tivozanib plus durvalumab in first line HCC Two trials in progress posters presentations for the DEDUCTIVE HCC study and the recently initiated Phase 1b/2 IMMCO-1 study of tivozanib and atezolizumab in multiple immunologically cold tumors Excerpt from the Press Release:…
Read More– Phase 1/2 trial of E-602 expected to open in Q1 2022 in patients with solid tumors – Excerpt from the Press Release: WALTHAM, Mass.–(BUSINESS WIRE)–Palleon Pharmaceuticals, a company pioneering the field of glyco-immunology to treat cancer and inflammatory diseases, today announced that the U.S. Food and Drug Administration has cleared the company’s investigational new…
Read MoreVT1021 Selected by Global Coalition for Adaptive Research (GCAR) for Inclusion in Its GBM AGILE Phase 2-3 Adaptive Platform Trial for Patients with Glioblastoma Excerpt from the Press Release: CAMBRIDGE, Mass., Jan. 20, 2022 /PRNewswire/ — Vigeo Therapeutics, a clinical-stage immuno-oncology company pioneering novel cancer therapies, today announced its lead candidate VT1021 will advance into a Phase 2-3 registrational…
Read More